US5618563A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Biodegradable polymer matrices for sustained delivery of local anesthetic agents
Assignee: Boston Children's Hospital
•
Filing: 1993-09-10
•
Granted: 1997-04-08
•
Expires: 2013-09-10
Abstract
Abstract An improved biodegradable controlled release system consisting of a polymeric matrix incorporating a local anesthetic for the prolonged administration of the local anesthetic agent, and a method for the manufacture thereof, are disclosed. The polymers and method of manufacture used to form the PLAMs are selected on the basis of their degradation profiles: release of the topical anesthetic in a linear, controlled manner over a period of preferably two weeks and degradation in vivo with a half-life of less than six months, more preferably two weeks, to avoid localized inflammation. Alternatively, a non-inflammatory can be incorporated into the polymer with the local anesthetic to prevent inflammation.
Inventors
- 👤 Charles B. Berde
- 👤 Robert S. Langer
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 04:23
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/44; A61K31/445; A61K31/16; A61K31/165; A61K31/167; A61K31/21; A61K31/215; A61K31/235; A61K31/24; A61K31/245; A61K31/47; A61K9/00; A61K9/14; A61K9/16; A61K9/1605; A61K9/1629; A61K9/1641; A61K9/20; A61K9/2004; A61K9/2022; A61K9/2031; A61P; A61P25/00; A61P25/02; A61K9/0012; A61K9/0019; A61K9/0024
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
105 words
A method for sustained local anesthesia or regional nerve blockade at a site in a patient, the improvement comprising administering by injection into tissue a local anesthetic incorporated into microparticles formed of a biocompatible polymer degrading at least fifty percent in less than six months following injection into the patient which is selected from the group consisting of polyanhydrides, copolymers of lactic acid and glycolic acid, poly(glycolic acid), polyorthoesters, proteins, and polysaccharides, wherein the local anesthetic is uniformly incorporated into the microparticles in a concentration effective to achieve sustained release of anesthetic at the site for at least three days following injection of the microparticles.
Claim 2
Independent Claim
105 words
A method for sustained local anesthesia or regional nerve blockade at a site in a patient, the improvement comprising administering by injection into tissue a local anesthetic incorporated into microparticles formed of a biocompatible polymer degrading at least fifty percent in less than six months following injection into the patient which is selected from the group consisting of polyanhydrides, copolymers of lactic acid and glycolic acid, poly(glycolic acid), polyorthoesters, proteins, and polysaccharides, wherein the local anesthetic is uniformly incorporated into the microparticles in a concentration effective to achieve sustained release of anesthetic at the site for at least three days following injection of the microparticles.
Claim 3
Dependent Claim
18 words
The method of claim 1 wherein the microparticles are selected from the group consisting of microspheres and microcapsules.
Claim 4
Dependent Claim
25 words
The method of claim 1 wherein the local anesthetic is selected from the group consisting of bupivacaine, dibucaine, etidocaine, tetracaine, lidocaine, xylocaine and salts thereof.
Claim 5
Dependent Claim
25 words
The method of claim 1 wherein the local anesthetic is incorporated into the microparticles at a percent loading of between 0.1% and 70% by weight.
Claim 6
Dependent Claim
15 words
The method of claim 1 wherein the microparticles are made using a hot melt process.
Claim 7
Dependent Claim
20 words
The method of claim 1 wherein the polymer does not elicit inflammation following injection of the microparticles into a patient.
Claim 8
Dependent Claim
19 words
The method of claim 2 further comprising administering the microparticles in combination with a pharmaceutically acceptable carrier by injection.
References Cited (Backward Citations)
US3185625A
Cited
US3755558A
Cited
US4039653A
Cited
US4059686A
Cited
US4131648A
Cited
US4093709A
Cited
US4138344A
Cited
US3972995A
Cited
US4034758A
Cited
US4070347A
Cited
US4585651A
Cited
US4250163A
Cited
US4226848A
Cited
US4622244A
Cited
US4369172A
Cited
US4434153A
Cited
US4530840A
Cited
US4542025A
Cited
US4568535A
Cited
US4906474A
Cited
US4946929A
Cited
US4597960A
Cited
US4569837A
Cited
US4685883A
Cited
US4652441A
Cited
US4591496A
Cited
US4753652A
Cited
US4891225A
Cited
US4886870A
Cited
US4779806A
Cited
EP0195906A2
Cited
US4650665A
Cited
US4568536A
Cited
US4638045A
Cited
US4863735A
Cited
US4900556A
Cited
US4713244A
Cited
US4732155A
Cited
US4806621A
Cited
US4735945A
Cited
US4780320A
Cited
EP0244118A1
Cited
US4919939A
Cited
US4757128A
Cited
US4933185A
Cited
US4789724A
Cited
US5075109A
Cited
US4861627A
Cited
US4921737A
Cited
US4916204A
Cited
US4933431A
Cited
US4857311A
Cited
US4898734A
Cited
US5122367A
Cited
US5188837A
Cited
US5227165A
Cited
WO1991017772A1
Cited
WO1992007555A1
Cited
WO1993020138A2
Cited
WO1995009613A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-04-07 | 2000-10-07 | 2001-04-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-04-07 | 2004-10-07 | 2005-04-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-04-07 | 2008-10-07 | 2009-04-08 | $7700.00 | Window Closed / Lapsed |